NextPharma Deal Next Step Toward US Distribution of Epigenomics' Colon Cancer Dx
October 07, 2010
NextPharma Deal Next Step Toward US Distribution of Epigenomics' Colon Cancer Dx
Germany's Epigenomics and life science outsourcing firm NextPharma have signed a global manufacturing contract covering Epi proColon, Epigenomics' nucleic acid amplification-based colorectal cancer screening test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.